Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
07:50am, Wednesday, 27'th Dec 2023
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic
Yes Virginia, There Is a Santa Claus Rally
06:47pm, Tuesday, 26'th Dec 2023
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Bristol to Buy Drug Developer RayzeBio for $4.1 Billion
02:46pm, Tuesday, 26'th Dec 2023
Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller repo
The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio
02:01pm, Tuesday, 26'th Dec 2023
Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
12:15pm, Tuesday, 26'th Dec 2023
RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options.
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
11:55am, Tuesday, 26'th Dec 2023
Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive te
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio
11:33am, Tuesday, 26'th Dec 2023
Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has made its second major acquisition in the span of a week, this time buying cancer drug developer RayzeBio in a $4.1 billion deal. The deal va
Acquisitions Push 2 Pharma Stocks in Opposite Directions
10:24am, Tuesday, 26'th Dec 2023
Pharmaceutical giants AstraZeneca plc (NASDAQ:AZN) and Bristol-Myers Squibb Co (NYSE:BMY) announced new acquisitions today.
Bristol Myers to buy RayzeBio for about $4.1B
08:55am, Tuesday, 26'th Dec 2023
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
07:16am, Tuesday, 26'th Dec 2023
RayzeBio is being bought for $62.50 a share in cash.
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
07:11am, Tuesday, 26'th Dec 2023
Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers
6 Reasons to Avoid Johnson & Johnson (JNJ) At All Costs
10:26am, Sunday, 24'th Dec 2023
Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
04:10pm, Saturday, 23'rd Dec 2023
Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar
12:00pm, Saturday, 23'rd Dec 2023
BMY remains a speculative dividend play here, with it remaining to be seen when the correction may end and if the floor may hold at $48s. While Revlimid's top-line erosion appears to be decelerating,
Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal
06:29pm, Friday, 22'nd Dec 2023
Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.
